HIV Treatment
Coverage of 21st International AIDS Conference (AIDS 2016)
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.
Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.
7/28/16
AIDS 2016: START Analysis Looks at Who Benefits Most from Immediate HIV Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by Liz Highleyman
Starting antiretroviral therapy (ART) soon after HIV diagnosis led to better outcomes than delayed treatment in all population subgroups in the START trial, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban. But some people saw greater risk reductions, including those over age 50, those with a lower CD4:CD8 ratio and higher viral load, and those with cardiovascular risk factors.
AIDS 2016: Early HIV Treatment -- Mothers Say They Need Time to Think
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by Carole Leach-Lemens
Findings from the first randomized controlled trial to date evaluating postpartum antiretroviral therapy (ART) for women with high CD4 cell counts (over 400 cells/mm3) highlight a critical need to increase treatment acceptance in this population, according to research presented at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
AIDS 2016: Starting Treatment on the Day of HIV Diagnosis Improves Outcomes
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by Keith Alcorn
Interventions to improve linkage to HIV care and retention in treatment which speed up the start of antiretroviral therapy (ART) or provide intensive support to people before starting treatment produce better retention than standard practices, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
AIDS 2016: Once-Daily Raltegravir Works as Well as Twice-Daily For Initial HIV Treatment
- Details
- Category: HIV Treatment
- Published on Monday, 25 July 2016 00:00
- Written by Liz Highleyman
A new formulation of the integrase inhibitor raltegravir (Isentress) taken once daily suppressed HIV viral load as well as the older formulation taken twice a day in people being treated for the first time, according to findings from the ONCEMRK study presented in a late-breaker session at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
More Articles...
- AIDS 2016: Dolutegravir Plus Lamivudine Works Well as First-Line HIV Treatment
- AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy
- AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function
- AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment
Web Design and Development by